<DOC>
	<DOCNO>NCT02229149</DOCNO>
	<brief_summary>This randomized phase 2 study seek determine effectiveness chemotherapy ( physician 's choice vinorelbine , taxane [ paclitaxel , docetaxel nab paclitaxel ] capecitabine ) plus trastuzumab v chemotherapy ( physician 's choice ) plus trastuzumab plus pertuzumab woman HER2-overexpressing metastatic breast ( MBC ) previously treat ado-trastuzumab emtansine ( T-DM1 ) metastatic setting .</brief_summary>
	<brief_title>Phase 2 Study Standard Chemotherapy With Trastuzumab , Plus Minus Pertuzumab , Pre-treated Metastatic Breast Cancer</brief_title>
	<detailed_description>The current preferred first-line therapy patient HER2-overexpressing metastatic breast cancer ( MBC ) taxane plus trastuzumab plus pertuzumab , base result CLEOPATRA trial . For patient disease progress trastuzumab taxane , ado-trastuzumab emtansine ( T-DM1 ) recently approve base result EMILIA trial show superiority setting compare capecitabine plus lapatinib . However , standard first-line therapy may change near future , result become available MARIANNE trial , evaluate T-DM1 alone combination pertuzumab upfront therapy . Two important question may raise finding study whether pertuzumab effective second- later-line therapy follow single-agent T-DM1 , whether pertuzumab administer beyond progression prior pertuzumab therapy clinical benefit trastuzumab proven . The study seek determine efficacy chemotherapy ( physician 's choice vinorelbine , taxane [ paclitaxel , docetaxel nab paclitaxel ] capecitabine ) plus trastuzumab v chemotherapy ( physician 's choice ) plus trastuzumab plus pertuzumab woman HER2-overexpressing MBC previously treat T-DM1 metastatic setting . We hypothesize addition pertuzumab trastuzumab plus chemotherapy improve median progression-free survival ( PFS ) , compare trastuzumab plus chemotherapy alone , second- later-line therapy patient receive prior T-DM1 . Patients stratify accord whether receive prior pertuzumab versus . We also explore whether continue treatment pertuzumab patient previously treat pertuzumab improve PFS .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Female , Age ≥ 18 year 2 . Histologic cytologic confirmation human epidermal growth factor receptor 2 ( HER2 ) positive breast cancer accord recent biopsy ( local testing permit ) 3 . Measurable evaluable metastatic disease Response Evaluation Criteria Solid Tumors ( RECIST ) ( v1.1 ) 4 . Previous treatment adotrastuzumab emtansine ( TDM1 ) metastatic disease . Prior therapy pertuzumab allow require 5 . At least 1 3 prior chemotherapy regimens metastatic breast cancer ( MBC ) 6 . Life expectancy &gt; 6 month 7 . Eastern Cooperative Group ( ECOG ) performance status ≤ 2 8 . Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % baseline determine either echocardiogram ( ECHO ) Multi Gated Acquisition Scan ( MUGA ) within normal limit per institutional guideline 9 . Adequate bone marrow function indicate follow : 1 . Absolute Neutrophil Count ( ANC ) ≥1500/uL ( 1500 per microliter ) 2 . Platelets ≥100,000/uL 3 . Hemoglobin &gt; 9 g/dL 10 . Adequate renal function , indicate creatinine &lt; 1.5 time upper limit normal ( ULN ) 11 . Adequate liver function , indicate bilirubin &lt; 1.5 time ULN 12 . Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) &lt; 2 x ULN unless liver metastasis present case AST ALT 5.x ULN allow 13 . Negative serum pregnancy test within 72 hour start study medication woman childbearing potential 14 . Women childbearing potential must willing use acceptable form birth control ( ie , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study Note : Women consider postmenopausal childbearing potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) , undergone surgical sterilization . 15 . Signed informed consent obtain prior screen procedure . Patients exclude study base follow criterion : 1 . Prior treatment metastatic setting agent choose physician 's choice chemotherapy 2 . Active infection 3 . Uncontrolled central nervous system metastasis , define clinical radiologic evidence progression brain metastasis clinical sign leptomeningeal disease . Patients treat brain metastasis eligible provide clinical radiologic evidence disease progression dexamethasone least 3 week 4 . Patient pregnant lactate 5 . Prior chemotherapy within last 3 week ( last 6 week nitrosureas/mitomycin ) 6 . Prior radiation therapy within last 2 week ; prior radiation therapy indicator lesion ( unless objective disease recurrence progression within radiation portal document since completion radiation ) . 7 . Requirement chronic steroid therapy requirement &gt; 5mg/day prednisone equivalent . . Treatment physiologic dose hydrocortisone 20 mg daily ( QD ) allow . 8 . Requirement immunosuppressive therapy , use treat autoimmune disease . 9 . Concomitant malignancy previous malignancy within last 3 year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix . 10 . History significant cardiac disease , cardiac risk factor uncontrolled arrhythmias 11 . Ejection fraction &lt; 50 % low limit institutional normal range , whichever low 12 . Known hypersensitivity trastuzumab pertuzumab 13 . Serious medical psychiatric limitation likely interfere participation study . 14 . Symptomatic intrinsic lung disease extensive tumor involvement lung , result dyspnea rest require supplemental oxygen 15 . Patient currently part participate clinical trial investigational agent within 1 month prior enrollment study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>HER2+ breast cancer</keyword>
</DOC>